Table 4.

Secondary Efficacy Analysis at Week 12: ITT Patient Population, % of Patients LOCF

Placebo (n=127)500 mg Citicoline (n=267)
Death18%17%NS
Barthel ≥9540%40%NS
Rankin ≤125%27%NS
NIHSS ≤124%27%NS
Hospital stay: d, median7.57.5NS